肿瘤新生血管及分子靶向治疗新策略

2011-12-04 MedSci原创 MedSci原创

    肿瘤血管靶向治疗是基于肿瘤新生血管与正常血管的不同, 药物专一识别并阻断肿瘤新生血管, 使肿瘤细胞“饿死”, 而不影响正常细胞。从1971 年Folkman 提出“饿死肿瘤” 的假说到2004 年第一个血管靶向药物上市, 记载着30 多年领域发展的传奇经历。当今, 肿瘤血管已成为生物医学和临床研究的热点, 新的发现层出不穷。该文重点介绍肿瘤血管新靶点、新机制、

    肿瘤血管靶向治疗是基于肿瘤新生血管与正常血管的不同, 药物专一识别并阻断肿瘤新生血管, 使肿瘤细胞“饿死”, 而不影响正常细胞。从1971 年Folkman 提出“饿死肿瘤” 的假说到2004 年第一个血管靶向药物上市, 记载着30 多年领域发展的传奇经历。当今, 肿瘤血管已成为生物医学和临床研究的热点, 新的发现层出不穷。该文重点介绍肿瘤血管新靶点、新机制、新药物与未来发展。

肿瘤新生血管及分子靶向治疗新策略.pdf

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703963, encodeId=86791e03963ad, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 18 05:57:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986918, encodeId=08bf1986918cc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sun Jun 17 10:57:00 CST 2012, time=2012-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748773, encodeId=23331e4877379, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Wed Nov 07 13:57:00 CST 2012, time=2012-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478328, encodeId=670714e83285b, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Tue Dec 06 02:57:00 CST 2011, time=2011-12-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703963, encodeId=86791e03963ad, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 18 05:57:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986918, encodeId=08bf1986918cc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sun Jun 17 10:57:00 CST 2012, time=2012-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748773, encodeId=23331e4877379, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Wed Nov 07 13:57:00 CST 2012, time=2012-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478328, encodeId=670714e83285b, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Tue Dec 06 02:57:00 CST 2011, time=2011-12-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1703963, encodeId=86791e03963ad, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 18 05:57:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986918, encodeId=08bf1986918cc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sun Jun 17 10:57:00 CST 2012, time=2012-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748773, encodeId=23331e4877379, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Wed Nov 07 13:57:00 CST 2012, time=2012-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478328, encodeId=670714e83285b, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Tue Dec 06 02:57:00 CST 2011, time=2011-12-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703963, encodeId=86791e03963ad, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 18 05:57:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986918, encodeId=08bf1986918cc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sun Jun 17 10:57:00 CST 2012, time=2012-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748773, encodeId=23331e4877379, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Wed Nov 07 13:57:00 CST 2012, time=2012-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478328, encodeId=670714e83285b, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Tue Dec 06 02:57:00 CST 2011, time=2011-12-06, status=1, ipAttribution=)]

相关资讯

2011年度肿瘤领域十大突破

  在2011年,多种癌症的科研和实践都取得了巨大进步,Medscape评论员们挑选了2011年肿瘤学的10大突破事件,下面将一一展示。 1.恶性黑色素瘤前所未有的进展         在2011年,2个研究和2个药物批准带来了转移性黑色素瘤的革命。自从在2011年ASCO年会上突出报告了两种药物对转移性黑色素瘤

欧盟EMA调整多种抗肿瘤药物的适应证和禁忌证

11月18日,欧洲药品管理局(EMA)建议批准甲状腺癌治疗药物凡德他尼(vandetanib)的上市申请,同时还批准了另外两种抗肿瘤药物西妥昔单抗(cetuximab)和曲妥珠单抗(trastuzumab)的新增适应证。 作为一种可有效对抗RET(转染过程中重排)原癌基因、血管内皮生长因子和表皮生长因子受体的口服蛋白激酶抑制剂,凡德他尼(由阿斯利康公司开发)将获准在所有欧盟国家上市,用于进展性或

糖尿病与肿瘤:悬疑之案

 MedSci点评:  糖尿病与肿瘤争议近100年了!至今仍然众说纷芸。 支持糖尿病与肿瘤的关系论点包括:(1)胰岛素抵抗,或胰岛素治疗,可能使血清中胰岛素水平相对增高,而胰岛素具有促进肿瘤细胞增长的作用;(2)不少治疗糖尿病的药物,具有增加肿瘤的风险;(3)血清中IGF-1与肿瘤发生正相关。(4)与糖尿病相关的伴随情况与肿瘤密切相关。如糖尿病患者往往伴随免疫水平的

Nat Comm:miRNA广泛参与癌细胞转移调控

    来自北京大学的研究人员利用高通量筛查技术对各种类型的癌细胞进行了miRNA组学分析,证实miRNA广泛地参与了癌细胞转移调控,并从中发现了一种多向调控癌症转移的抑制因子miR-23b。这一研究成果在线发表在11月22日的《自然—通讯》(Nature communications)杂志上。 领导这一研究的是北京大学工学院生物医学工程系席建忠(Jianzhong

Nat Med:新药KG5能有效破坏肿瘤

11月14日,据美国媒体报道,美国科学家研制出一种名为KG5的新药,能通过依附于酶RAF之上并改变其结构来抑制几乎所有肿瘤细胞的分裂,从而破坏增生能力最强的肿瘤。科学家们表示:“这个非同寻常的新成果能真正挑战现有的医学教条。”相关研究发表在11月13日出版的《自然·医学》网络版上。 目前攻击RAF等酶的抗癌药物一般都被设计成同酶的活性部位相互作用,但这样常常会使其缺乏针对性。为避免现有药物的